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recessively inherited through segregation studies. The 
affected amino acid has been reported as a Dutch founder 
mutation p.(Asp92Tyr) in families with hereditary head and 
neck paraganglioma. By introducing both mutations into 
Saccharomyces cerevisiae, we were able to confirm that 
the p.(Asp92Gly) mutation causes a more severe oxida-
tive growth phenotype than the p.(Asp92Tyr) mutant, and 
provides functional evidence to support the pathogenicity 
of the patient’s SDHD mutation. This is only the second 
case of mitochondrial complex II deficiency due to inher-
ited SDHD mutations and highlights the importance of 
sequencing all SDH genes in patients with biochemical and 
histochemical evidence of isolated mitochondrial complex 
II deficiency.
Introduction
Mitochondrial respiratory chain disease arises from defec-
tive oxidative phosphorylation (OXPHOS) and represents 
a common cause of metabolic disease with an estimated 
prevalence of 1:4300 (Gorman et al. 2015; Skladal et al. 
2003). Under aerobic conditions, metabolised glucose, 
fatty acids and ketones are the OXPHOS substrates, shut-
tling electrons along the respiratory chain whilst concomi-
tantly creating a proton gradient by actively transporting 
protons across the mitochondrial membrane. The resultant 
proton gradient is exploited by ATP synthase to drive ATP 
production. Under anaerobic conditions, for example where 
atmospheric oxygen is scarce or during periods of exer-
tion, ATP synthesis is produced primarily during glycolysis 
(Horscroft and Murray 2014).
The mitoproteome consists of an estimated 1400 pro-
teins (Pagliarini et al. 2008), including the 13 polypeptides 
and 24 non-coding tRNA and rRNA genes encoded by the 
Abstract Succinate dehydrogenase (SDH) is a crucial 
metabolic enzyme complex that is involved in ATP pro-
duction, playing roles in both the tricarboxylic cycle and 
the mitochondrial respiratory chain (complex II). Isolated 
complex II deficiency is one of the rarest oxidative phos-
phorylation disorders with mutations described in three 
structural subunits and one of the assembly factors; just 
one case is attributed to recessively inherited SDHD muta-
tions. We report the pathological, biochemical, histochemi-
cal and molecular genetic investigations of a male neonate 
who had left ventricular hypertrophy detected on ante-
natal scan and died on day one of life. Subsequent post-
mortem examination confirmed hypertrophic cardiomyo-
pathy with left ventricular non-compaction. Biochemical 
analysis of his skeletal muscle biopsy revealed evidence 
of a severe isolated complex II deficiency and candidate 
gene sequencing revealed a novel homozygous c.275A>G, 
p.(Asp92Gly) SDHD mutation which was shown to be 
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mitochondria’s own genetic material (mtDNA) that are 
exclusively maternally transmitted. The remaining genes 
of the mitoproteome are located on either the autosomes 
or sex chromosomes and as such are transmitted from par-
ent to child in a Mendelian fashion. Defects in a number 
of mtDNA and nuclear-encoded genes have been linked 
to human disease, often associated with a vast genetic and 
clinical heterogeneity and further compounded by few gen-
otype–phenotype correlations which help guide molecular 
genetic investigations.
Succinate dehydrogenase is a crucial metabolic enzyme 
complex that is involved in both the Krebs cycle and the 
mitochondrial respiratory chain. It is composed of two 
catalytic subunits (the flavoprotein SDHA, and Fe–S-con-
taining SDHB) anchored to the inner mitochondrial mem-
brane by the SDHC and SDHD subunits. All four subu-
nits and the two known assembly factors are encoded by 
autosomal genes (SDHA, SDHB, SDHC, SDHD, SDHAF1 
and SDHAF2, hereafter referred to as SDHx). Congenital 
recessive defects involving SDHx genes are associated with 
diverse clinical presentations, including leukodystrophy 
and cardiomyopathy (Alston et al. 2012).
A recent review describes SDHA mutations as the most 
common cause of isolated complex II deficiency, with 16 
unique mutations reported in 30 patients (Ma et al. 2014; 
Renkema et al. 2014); the next most common cause are 
mutations in SDHAF1, 4 mutations have been reported in 
13 patients (Ghezzi et al. 2009; Ohlenbusch et al. 2012). 
Just one mitochondrial disease patient is reported to har-
bour either SDHB (Alston et al. 2012) or SDHD (Jackson 
et al. 2014) mutations and metabolic presentations have yet 
to be reported in association with SDHC or SDHAF2.
In addition to their role in primary respiratory chain dis-
ease, SDHx mutations can act as drivers of neoplastic trans-
formation following loss of heterozygosity (LOH). One of 
the most common causes of head and neck paraganglioma 
(HNPGL) is LOH at the SDHD locus. These mutations 
are inherited in a dominant manner with a parent of origin 
effect; typically only paternally inherited SDHD mutations 
are associated with HNPGL development (Hensen et al. 
2011).
Here, we report a neonate who presented prenatally with 
cardiomyopathy due to a novel homozygous SDHD muta-
tion. This is the second report of recessive SDHD mutations 
resulting in a primary mitochondrial disease presentation 
and serves to characterise the biochemical, histochemical 
and functional consequences of our patient’s molecular 
genetic defect. Moreover, the affected amino acid, p.Asp92, 
has been reported as a Dutch founder mutation in families 
with hereditary PGL, albeit the substituted residue differs. 
We have used the yeast, Saccharomyces cerevisiae, which 
has proven to be a useful model system to study the effects 
of SDHx gene mutations (Goffrini et al. 2009; Panizza 
et al. 2013), to provide functional evidence supporting 
the pathogenicity of the SDHD mutation identified in our 
patient and, to a lesser extent, that of the PGL-associated 
p.Asp92Tyr mutation.
Patient and methods
The patient is the third child born to unrelated Irish parents. 
Foetal heart abnormalities were identified on an anomaly 
scan at 31-weeks gestation, which prompted foetal echo-
cardiography. A normally situated heart with normal sys-
temic and pulmonary venous drainage was reported. Right 
to left shunting was noted at the patent foramen ovale and 
ductus arteriosus, consistent with gestational age. The left 
ventricle and left atrium were severely dilated with mod-
erate–severe mitral regurgitation. There was severe left 
ventricular systolic dysfunction, but no evidence of peri-
cardial effusion or ascites. Rhythm was normal sinus with 
a foetal heart rate between 100 and 120 beats per minute 
and subsequent weekly foetal echocardiogram showed no 
further progression of cardiac dysfunction or development 
of hydrops. Cardiac MRI at 32-weeks gestation showed 
marked left ventricular hypertrophy and dilation. A clinical 
diagnosis of dilated cardiomyopathy was considered and 
the parents were counselled that the prognosis for postpar-
tum survival was poor. The proband was born by elective 
caesarean section at 37 + 6 weeks gestation with a birth 
weight of 2620 g (9th–25th centile) and occipital circumfer-
ence of 34.5 cm (50th–75th centile). He had no dysmorphic 
features. He was transferred to neonatal intensive care on 
100 % oxygen to maintain his saturations in the low 90 s. 
An additional heart sound and loud murmur were noted, 
along with hepatomegaly (4 cm below costal margin) but 
without splenomegaly. By 12 h of age, his condition had 
deteriorated significantly; echocardiogram showed dilation 
of the inferior vena cava, hepatic veins, right atrium and 
interatrial septal bowing. He had moderate tricuspid regur-
gitation and very poor biventricular function with non-
compaction hypertrophy. The proband died the following 
evening following withdrawal of life support with parental 
consent. At postmortem examination, the heart weighed 
43 g (normal = 13.9 ± 5.8 g). The right atrium was par-
ticularly enlarged. The endocardium of the right atrium but 
particularly also the right ventricle showed fibroelastosis. 
The right ventricle was remarkably diminutive and under-
developed. The right atrium had a 7-mm-diameter patent 
foramen ovale. There was obvious non-compaction of the 
hypertrophic left ventricular myocardium (Fig. 1). Cardiac 
muscle, skeletal muscle and a skin biopsy were referred for 
laboratory investigations. Informed consent was obtained 
from the parents for the clinical and laboratory investiga-
tions and publication of the results.
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Histochemical and biochemical assessment 
of metabolic function
Histological and histochemical assay of 10 μm serial sec-
tions of patient muscle biopsy was performed according to 
standard protocols. The measurement of respiratory chain 
enzyme activities was determined spectrophotometrically 
as described previously (Kirby et al. 2007). Fibroblast cul-
ture and measurement of β-oxidation flux in cultured fibro-
blasts using [9, 10-3H] myristate, [9, 10-3H]palmitate and 
[9, 10-3H]oleate was performed as described elsewhere 
(Manning et al. 1990; Olpin et al. 1992, 1997).
Cytogenetic and molecular genetic investigations
Karyotyping of cultured fibroblasts and DNA extraction 
from patient muscle were performed according to standard 
protocols. Primers were designed to amplify each coding 
exon, plus intron–exon boundaries, of the SDHA, SDHB, 
SDHC, SDHD, SDHAF1 and SDHAF2 genes. PCR ampli-
cons were Sanger sequenced using BigDye3.1 chemistry 
(Applied Biosystems) and capillary electrophoresed on 
an ABI3130xl bioanalyser (Applied Biosystems) using 
standard methodologies. Resultant sequencing chromato-
grams were compared to the Genbank reference sequences: 
SDHA (NM_004168.2), SDHB (NM_003000.2), SDHC 
(NM_003001.3), SDHD (NM_003002.3), SDHAF1 
(NM_001042631.2) and SDHAF2 (NM_017841.2). All 
gene variants were annotated using dbSNP build 138 whilst 
ESP6500 and 10 k genome project data allowed determi-
nation of allele frequencies. Parental DNA samples were 
screened to investigate allele transmission.
In silico pathogenicity prediction tools 
and structural modelling
The effect of the p.(Asp92Gly) substitution on SDHD func-
tion was predicted using the in silico tools SIFT (Ng and 
Henikoff 2003), Align GVGD (Tavtigian et al. 2006) and 
Polyphen (Adzhubei et al. 2010), all running recommended 
parameters. To determine whether the tertiary structure 
of the protein was affected by the mutation, the wild-type 
(NP_002993) and mutant SDHD protein sequences were 
input to PSIPRED (Jones 1999) and I-TASSER (Yang et al. 
2014); I-TASSER output was visualised using UCSF Chi-
mera (Pettersen et al. 2004).
Blue native polyacrylamide gel electrophoresis 
(BN‑PAGE)
Mitochondria-enriched pellets were obtained from 15 mg 
skeletal muscle as previously described (Nijtmans et al. 
2002) and solubilised in 1× sample buffer (Invitrogen, 
Fig. 1  Macroscopic and microscopic analysis of patient cardiac and 
skeletal muscle. a Macroscopic examination of patient heart revealed 
obvious non-compaction of the hypertrophic left ventricle. b Micro-
scopic assessment of left ventricle confirms non-compaction com-
pared to neonatal control tissue (c). Histochemical assessment of 
patient muscle biopsy shows a marked decrease in the activity of suc-
cinate dehydrogenase activity (d) compared with a control muscle (e)
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BN20032), 2 % dodecyl-β-d-maltoside (Sigma) and 
5 % glycerol. Mitochondria were pelleted for 15 min at 
100,000 g. Protein concentrations were determined by 
Pierce™ BCA Protein Assay Kit according to manu-
facturer’s protocol (ThermoScientific). Protein sam-
ples (25 μg) were separated on NativePAGE™ Novex® 
4–16 % Bis–Tris Protein Gels (Sigma) then transferred 
onto a PVDF membrane. Immunodetection of assem-
bled respiratory chain complexes was performed using 
primary monoclonal antibodies (mitosciences) raised 
against complex-specific proteins: Complex I (NDUFB8, 
Abcam, ab110242), Complex II (SDHA, MitoSciences, 
MS204), Complex III (CORE2 Abcam, ab14745), 
Complex IV (COX1 Abcam, ab14705) and Complex 
V (ATP5A Abcam, ab14748). Following HRP-conju-
gated secondary antibody application (Dako), detection 
was undertaken using the ECL® plus chemilumines-
cence reagent (GE Healthcare Life Sciences, Bucking-
hamshire, UK) and a ChemiDoc MP imager (Bio-Rad 
Laboratories).
Western blot
Mitochondria-enriched pellets prepared as above were 
lysed on ice in 50 mM Tris pH 7.5, 130 mM NaCl, 2 mM 
MgCl2, 1 mM PMSF and 1 % NP-40. Protein concentra-
tion was calculated using the Bradford method (Brad-
ford 1976). 13 µg of enriched mitochondrial proteins was 
loaded on a 12 % sodium dodecyl sulphate polyacryla-
mide gel with 1× dissociation buffer, electrophoretically 
separated and subsequently transferred onto a PVDF 
membrane. Immunodetection was performed using pri-
mary antibodies raised against complex II SDHA (Mito-
Sciences, MS204) and SDHD (Merck Millipore, ABT110) 
and a mitochondrial marker protein, Porin (Abcam, 
ab14734). Following secondary antibody application 
(Dako), detection was undertaken using the ECL® plus 
chemiluminescence reagent (GE Healthcare Life Sciences, 
Buckinghamshire, UK) and ChemiDoc MP imager (Bio-
Rad Laboratories).
Yeast strains and media
Yeast strains used in this study were BY4741 (MATa; 
his3∆1 leu2∆0 met15∆0 ura3∆0) and its isogenic 
sdh4:kanMX4. Cells were cultured in yeast nitrogen 
base (YNB) medium: 0.67 % yeast nitrogen base without 
amino acids (ForMediumTM), supplemented with 1 g/l of 
drop-out powder (Kaiser et al. 1994) containing all amino 
acids and bases, except those required for plasmid main-
tenance. Various carbon sources (Carlo Erba Reagents) 
were added at the indicated concentration. For the respi-
ration and mitochondria extraction, cells were grown to 
late-log phase in the YNB medium supplemented with 
0.6 % glucose. Media were solidified with 20 g/l agar 
(ForMediumTM) and strains were incubated at 28 or 
37 °C.
Construction of yeast mutant alleles
The sdh4Asp98Gly and sdh4Asp98Tyr mutant alleles 
were obtained by site-directed mutagenesis using the 
overlap extension technique (Ho et al. 1989). In the first 
set of PCR reactions, the SDH4 region was obtained 
using the forward primer ESDH4F and the following 
reverse mutagenic primer sdh4R98G 5′-CATGACAG 
AAAAGAAAGAACCAGCTGCAGTGGATAACGG 
AC-3′ and sdh4R98Y 5′-CATGACAGAAAAGAAAG 
AGTAAGCTGCAGTGGATAACGGAC-3′ where base 
changes are indicated in bold. The second SDH4 region 
was obtained using the forward mutagenic primer 
sdh4F98G and sdh4F98Y, complementary to sdh4R98G 
and sdh4R98Y, and the reverse primer XSDH4R. The 
final mutagenized products were obtained using the 
overlapping PCR fragments as template with ESDH4F 
and XSDH4R as external primers. The products were 
then digested with EcoRI and XbaI and cloned in 
EcoRI–XbaI-digested pFL38 centromeric plasmid (Bon-
neaud et al. 1991). The mutagenized inserts were veri-
fied by sequencing and the pFL38 plasmid-borne SDH4 
and SDH4 mutant alleles were transformed in the 
BY4741 using the lithium-acetate method (Gietz and 
Schiestl 2007).
Isolation of mitochondria, enzyme assay 
and respiration
Oxygen uptake was measured at 28 °C using a Clark-type 
oxygen electrode in a 1-ml stirred chamber containing 
1 ml of air-saturated respiration buffer (0.1 M phthalate–
KOH, pH 5.0) and 10 mM glucose (Oxygraph System, 
Hansatech Instruments, England). The reaction was initi-
ated with the addition of 20 mg of wet weight of cells, as 
previously described (Goffrini et al. 2009). Preparation of 
mitochondria and succinate dehydrogenase DCPIP assay 
was conducted as described (Goffrini et al. 2009). The 
succinate:decylubiquinone DCPIP reductase assay was 
conducted as previously described (Jarreta et al. 2000; 
Oyedotun and Lemire 2001). Protein concentration was 
determined by the Bradford method using the Bio-Rad pro-
tein assay following the manufacturer’s instructions (Brad-
ford 1976).
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Results
Pathological, histochemical and biochemical analysis
Histopathological examination of the patient’s heart 
revealed non-compaction of the left ventricular myocar-
dium (Fig. 1a, b). Histological investigations reported 
normal skeletal muscle morphology whilst histochemi-
cal analysis of fresh-frozen muscle biopsy sections 
revealed a global reduction of succinate dehydrogenase 
(complex II) activity compared to aged-matched control 
samples (Fig. 1d, e). Spectrophotometric analysis of res-
piratory chain function in patient muscle homogenate 
revealed a marked defect in complex II activity (patient 
0.042 nmols/min/unit citrate synthase activity; controls 
0.145 ± 0.047 nmols/min/unit citrate synthase activity 
(n = 25) representing ~30 % residual enzyme activity; the 
activities of complex I, complex III and complex IV were 
all normal (not shown). Fatty acid oxidation flux studies 
on cultured fibroblasts gave normal results which excluded 
virtually all primary defects of long- and medium-chain 
fatty acid oxidation as the cause of the underlying cardiac 
pathology. There was no evidence of an underlying ami-
noacidopathy and serum urea and electrolytes were within 
normal limits. Investigations of glucose and lactate levels 
were not performed. The monolysocardiolipin/cardiolipin 
(ML/CL) ratio on a postmortem sample was 0.03 and the 
neutrophil count was within normal limits.
Cytogenetic and molecular genetic investigations
Karyotyping reported a normal 46 XY profile, consist-
ent with no large genomic rearrangements. Follow-
ing identification of an isolated complex II deficiency, 
Sanger sequencing of all six SDHx genes was under-
taken and a novel homozygous c.275A>G, p.(Asp92Gly) 
variant was identified in SDHD (ClinVar Reference ID: 
SCV000196921). Results from parental carrier test-
ing were consistent with an autosomal recessive inherit-
ance pattern, with each parent harbouring a heterozygous 
c.275A>G, p.(Asp92Gly) SDHD variant (Fig. 2a). The 
p.Asp92 SDHD residue is highly conserved (Fig. 2d) 
and the c.275A>G variant is not reported on either the 
ESP6500 or 1KGP suggesting that it is rare in the general 
population. Whilst the c.275A>G, p.(Asp92Gly) SDHD 
variant has not been previously reported, another mutation 
affecting the same residue—c.274G>T, p.(Asp92Tyr)—
has been reported in association with familial PGL and 
PCC (Hensen et al. 2011). In silico predictions were 
strongly supportive of a deleterious effect; 100 % sensi-
tivity and 100 % specificity were reported by SIFT and 
polyphen for both the p.(Asp92Gly) and p.(Asp92Tyr) 
variants. Both variants were assigned an aGVGD class 
of C65 (highly likely to be detrimental to protein func-
tion)—the p.(Asp92Gly) variant was reported to have a 
grantham difference (GD) value of 93.77, whilst the GD 
for the p.(Asp92Tyr) variant was 159.94 (GD > 70 is 
associated with C55/C65 variant classes). SDHD tertiary 
structure was not predicted to be markedly impacted by 
the patient’s p.(Asp92Gly) substitution; no gross confor-
mational change was reported by I-TASSER (Fig. 2b), 
whilst PSIPRED predicted only a mild alteration to the 
helix structure (Fig. 2c).
Functional effect of the c.275A>G, p.(Asp92Gly) SDHD 
mutation on protein expression and complex assembly
Having identified an excellent candidate mutation, assess-
ment of respiratory chain complex assembly by one-
dimensional BN-PAGE revealed a marked decrease in 
fully assembled Complex II, whilst levels of fully assem-
bled complexes I, III, IV and V were comparable to con-
trols (Fig. 3a). Western blot of mitochondrial proteins in 
patient muscle was performed which confirmed a signifi-
cant reduction of the SDHD and SDHA proteins compared 
to both equally loaded control muscle samples and Porin, a 
mitochondrial marker protein (Fig. 3b).
Functional studies in a yeast model
To further assess the pathogenicity of the patient’s novel 
p.(Asp92Gly) SDHD variant, we performed complemen-
tation studies using a strain of S. cerevisiae lacking the 
SDH4 gene hereafter referred to as Δsdh4. The SDH4 
gene is the yeast orthologue of human SDHD and although 
the human and yeast protein have a low degree of conser-
vation (16 % identity and 36 % similarity) the p.Asp92 
residue is conserved between the two species, correspond-
ing to p.Asp98 in yeast (Fig. 2d). We then introduced the 
change equivalent to the human p.(Asp92Gly) variant into 
the yeast SDH4 wild-type gene cloned in a centromeric 
vector thus obtaining the sdh4D98G mutant allele. Since 
another mutation involving the same residue, p.(Asp92Tyr), 
has been reported as a cause of paraganglioma, a second 
mutant allele, sdh4D98Y, was also constructed to compare 
the phenotype between the two different amino acid sub-
stitutions. The SDH4, sdh4D98G and sdh4D98Y constructs 
and the empty plasmid pFL38 were then transformed into 
the Δsdh4 strain. To test the possible effects on mitochon-
drial function, we first evaluated the oxidative growth by 
spot assay analysis on mineral medium supplemented with 
either glucose or ethanol, at 28 and 37 °C.
A clear growth defect was observed for the Δsdh4/
sdh4D98G strain in ethanol-containing plates incubated both 
at 28 and 37 °C (Fig. 4a), with growth similar to that of 
the sdh4 null mutant. Contrariwise, the Δsdh4/sdh4D98Y 
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strain did not exhibit an OXPHOS-deficient phenotype 
at either temperature tested (Fig. 4b) or in either oxida-
tive carbon source analysed (not shown). To further inves-
tigate the OXPHOS defect, oxygen consumption and 
SDH activity were measured. The oxygen consumption 
rate of the Δsdh4/sdh4D98G mutant was 55 % less than 
that of the parental strain Δsdh4/SDH4 (Fig. 5a), like-
wise, succinate dehydrogenase enzyme activities (PMS/
DCPIP reductase and decylubiquinone reductase) were 
both severely reduced, with levels similar to those of the 
null mutant (Fig. 5b). Consistent with the results obtained 
from growth experiments the oxygen consumption rate 
of the Δsdh4/sdh4D98Y mutant was not impaired (Fig. 5a) 
but both SDH activities (PMS/DCPIP reductase and decy-
lubiquinone reductase) were partially reduced (80 and 
75 % residual activity) in Δsdh4/sdh4D98Y mitochondria 
(Fig. 5b). Together, these data support the pathogenicity of 
our patient’s novel p.(Asp92Gly) SDHD variant.
Discussion
Mitochondrial complex II deficiency is one of the rarest 
disorders of the OXPHOS system, accounting for between 
2 and 8 % of mitochondrial disease cases (Ghezzi et al. 
2009; Parfait et al. 2000) with only ~45 cases reported in 
Fig. 2  Molecular genetic and in silico investigations. a Identifica-
tion of a pathogenic SDHD mutation. A homozygous c.275A>G, 
p.(Asp92Gly) SDHD mutation was identified in the proband, with 
parental DNA screening supporting recessive inheritance. The 
mutation affects a highly conserved p.Asp92 residue in the SDHD-
encoded subunit of succinate dehydrogenase (SDH). b Structural 
modelling. I-TASSER prediction of control and patient SDHD ter-
tiary structure shows the p.Asp92 residue located within a transmem-
brane helix domain and the p.Asp92Gly substitution is predicted to 
have little impact on SDHD tertiary structure. c PSIPRED output pre-
dicts minor alterations to two of the SDHD helices from the patient 
p.(Asp92Gly) and HNPGL p.(Asp92Tyr) substitutions compared to 
control sequence. Predicted helix residues shown in pink; unshaded 
residues are located in coil domains. d Multiple sequence alignment 
of this region of the SDHD subunit was performed using ClustalW 
and confirms that the p.(Asp92Gly) mutation affects an evolutionary 
conserved residue (shaded). Alignments were manually corrected on 
the basis of the pairwise alignment obtained with PSI-BLAST
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the literature. We report a newborn boy presenting with left 
ventricular hypertrophy on foetal ultrasound at 32-weeks 
gestation who rapidly deteriorated after delivery due to 
cardiopulmonary insufficiency, dying on day one of life. 
Postmortem examination confirmed a non-compacted 
hypertrophic left ventricle but assessment of monolyso-
cardiolipin and cardiolipin levels excluded a diagnosis 
of Barth syndrome. Biochemical analysis of his muscle 
biopsy revealed evidence of a marked isolated complex 
II deficiency. Sequencing the genes involved in succinate 
dehydrogenase structure and assembly was undertaken and 
revealed a novel homozygous c.275A>G, p.(Asp92Gly) 
SDHD mutation which was shown to be recessively inher-
ited through segregation studies.
Fig. 3  Investigation of OXPHOS complex activities and protein 
expression in patient and controls. a BN-PAGE analysis of mitochon-
dria isolated from patient and control muscle homogenates revealed 
a reduction of assembled complex II in patient muscle with normal 
assembly of all other OXPHOS complexes. b SDS-PAGE analysis 
of patient and control proteins probed with antibodies against Porin 
(a loading control) and the SDHA and SDHD subunits of succinate 
dehydrogenase revealed a stark reduction in SDH steady-state protein 
levels in patient muscle, consistent with subunit degradation thereby 
supporting the pathogenicity of the p.(Asp92Gly) variant
Fig. 4  Oxidative growth 
phenotype in yeast. The strain 
BY4741 Δsdh4 was trans-
formed with a pFL38 plasmid 
carrying either the wild-type 
SDH4, the empty vector or 
the mutant alleles sdh4D98G 
and sdh4D98Y. Equal amounts 
of serially diluted cells from 
exponentially grown cultures 
(105, 104, 103, 102, 101) were 
spotted onto yeast nitrogen base 
(YNB) plates supplemented 
with either 2 % glucose or 2 % 
ethanol. The growth was scored 
after 3-day incubation at 28 °C 
(a) and 37 °C (b)
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Patients with an isolated complex II deficiency harbour 
either compound heterozygous or homozygous mutations 
in an SDH structural or assembly factor gene. The result-
ant loss of OXPHOS-driven ATP synthesis is associated 
with clinical presentations including Leigh syndrome, car-
diomyopathy and leukodystrophy, that often present dur-
ing infancy, though adult cases are reported (Taylor et al. 
1996; Birch-Machin et al. 2000). Complex II deficiency 
is very rare, perhaps reflecting an incompatibility with 
life for many cases and our patient’s clinical history with 
prenatal cardiomyopathy and rapid deterioration post-
partum supports this hypothesis. Although the published 
cohort of patients with complex II deficiency is small, 
mutations which affect the ability of complex II to bind to 
the mitochondrial membrane are evolving to be the most 
deleterious.
The only other SDHD-deficient patient reported in the 
literature harboured compound heterozygous variants, 
one missense and one that extended the protein by three 
amino acids (Jackson et al. 2014). The clinical presenta-
tion of this individual differed from that of our patient 
who presented in utero with a cardiomyopathy that was 
incompatible with life. The previously described case was 
delivered at term after a normal pregnancy and presented 
at age 3 months with developmental regression following 
a viral infection with progressive neurological deteriora-
tion (epileptic seizures, ataxia, dystonia and continuous 
intractable myoclonic movements) and died at the age of 
10 years. The patient described by Jackson et al. also had 
comparably low levels of SDHD protein on Western blot 
with greatly reduced levels of fully assembled complex II; 
a residual level of complex activity is therefore unlikely 
to account for the difference in presentation. We hypoth-
esised that the p.(Asp92Gly) variant might have caused a 
conformational change given the location of the conserved 
acidic p.Asp92 residue at the N-terminus of one of the 
protein’s helical domains. With this in mind, we modelled 
the predicted impact of the patient’s p.(Asp92Gly) SDHD 
mutation on tertiary structure using in silico methodolo-
gies. Contrary to our expectations, neither I-TASSER nor 
PSIPRED predicted gross tertiary structural anomalies 
due to the substitution, despite being situated between two 
conserved cysteine residues; the pathogenicity is therefore 
assumed to lie in the nature of the amino acid properties 
as opposed to consequential protein misfolding. The loca-
tion of the p.Asp92 residue at the helical N-termini may 
explain the discrepancy between the predicted Grantham 
scores and the functional data obtained following yeast 
modelling; leucine–tyrosine interactions are reported 
to act as stabilisers within alpha helices (Padmanabhan 
and Baldwin 1994) meaning the p.Asp92Tyr substitution 
(with a higher GD score) may therefore be less deleteri-
ous than the p.(Asp92Gly) substitution harboured by our 
patient. Moreover, the location of the substitution may 
also be important in capping the positive helical dipole, 
and replacement with a non-polar residue such as glycine 
would fail to provide the same charge stabilization. There 
was slight discordance between the helix predictions from 
Fig. 5  a Oxygen consump-
tion rates. Respiration was 
measured in cells grown in 
YNB supplemented with 
0.6 % glucose at 28 °C. The 
values observed for the sdh4 
mutant cells are reported as a 
percentage of the wild-type 
SDH4 cell respiratory rate, 
40.46 ± 1.54 nmol min−1 mg−1. 
b Complex II activity. PMS/
DCPIP reductase and decy-
lubiquinone reductase activities 
were measured in mitochondria 
extracted from cells grown 
exponentially at 28 °C in YNB 
supplemented with 0.6 % 
glucose. The values of the 
sdh4 mutants are expressed 
as percentage of the activities 
obtained in the wild-type strain
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I-TASSER and PSIPRED (Fig. 2b, c) but on closer inspec-
tion of the discordant residues, there was low confidence in 
the predictions.
Mutations in SDHD and other SDHx genes have been 
implicated not only in primary metabolic dysfunction, 
but also as drivers of neoplastic transformation in various 
tumour types. There is a wealth of information in the lit-
erature describing the involvement of SDHx gene mutations 
in cases of hereditary and sporadic cancers including head 
and neck paraganglioma, pheochromocytoma and gastro-
intestinal stromal tumours (Miettinen and Lasota 2014). In 
the context of hereditary cancer, each somatic cell harbours 
one heterozygous germline mutation either inherited from 
a parent or occurring de novo. This single loss-of-function 
allele, alone, is insufficient to cause neoplastic transforma-
tion but if a “second hit” affects the wild-type allele, the 
loss of SDH activity disrupts ATP production. The inabil-
ity of SDH to metabolise succinate causes a build-up of 
substrate, with elevated succinate levels stabilizing HIF1α. 
This in turn creates a pseudo-hypoxic state, prompting a 
switch to glycolytic respiration consistent with neopla-
sia (Hanahan and Weinberg 2011; Pollard et al. 2005). 
The metabolic stalling due to SDH dysfunction also acts 
to inhibit multiple 2-oxoglutarate-dependent histone and 
DNA demethylase enzymes resulting in widespread histone 
and DNA methylation, further adding to the tumorigenic 
burden of these already respiratory-deficient cells (Xiao 
et al. 2012).
To date, mutations reported in the SDHx genes are loss 
of function, either as tumour suppressors or in metabolic 
enzymes. The mutation harboured by our patient transcends 
these fields in that, although manifesting as a primary met-
abolic condition in our case, the p.Asp92 residue is recog-
nised as a Dutch founder HNPGL mutation, p.(Asp92Tyr). 
Given the established link between tumorigenesis and this 
residue, further functional investigations were undertaken 
to determine whether the p.(Asp92Gly) variant—associ-
ated with primary metabolic dysfunction—was as deleteri-
ous, or indeed more so, than the founder HNPGL mutation. 
Functional investigations were supportive of a deleterious 
effect, Western blotting of patient muscle homogenates 
revealed a reduction in the steady-state levels evident for 
not only SDHD, but also for SDHA. This was supported by 
one-directional BN-PAGE, which confirmed a decrease in 
fully assembled complex II, consistent with the hypothesis 
that an inability to anchor the unstable complex within the 
mitochondrial membrane triggers the recycling of interme-
diates to prevent aggregation. This turnover is seen in other 
cases of mitochondrial complex dysfunction and prevents 
accumulation and aggregation of assembly intermediates 
and surplus complex subunits (Alston et al. 2012).
To assess the pathogenic role of the novel p.(Asp92Gly) 
SDHD substitution, we carried out a series of experiments 
in yeast devoid of SDH4, the yeast SDHD orthologue. 
The use of ethanol or glucose as a carbon source tested 
the strains’ ability to rely upon either OXPHOS or fer-
mentation for ATP synthesis. The SDHD residue p.Asp92 
shows high evolutionary conservation and corresponds to 
p.Asp98 in yeast. Given that a germline mutation involv-
ing the same amino acid has been reported as a cause of 
paraganglioma [p.(Asp92Tyr)], two mutant alleles—
sdh4D98G and sdh4D98Y—were constructed to compare 
the phenotypes associated with the different substitutions. 
Consistent with the reduction of SDHD steady-state lev-
els and fully assembled complex II found in our patient, 
the p.(Asp92Gly) mutation was detrimental to both oxida-
tive growth and succinate dehydrogenase activity in yeast. 
Contrariwise, the p.(Asp98Tyr) HNPGL-associated substi-
tution did not affect oxidative growth and showed a mild, 
albeit significant, reduction of SDH activity. Altogether 
the results obtained in the yeast model provide compel-
ling functional evidence supporting the pathogenic role 
of the p.(Asp92Gly) mutation and show that this substi-
tution conveys a more severe phenotype than the founder 
HNPGL SDHD mutation, this finding is not unique as 
other PGL-associated SDHD mutations were found to 
cause a milder phenotype when modelled in yeast (Panizza 
et al. 2013). Whilst our modelling suggests that the well-
characterised p.(Asp92Tyr) PGL mutation is associated 
with what might be considered a mild phenotype in yeast, 
the phenotype in question is not a primary metabolic one 
and indeed it is only associated with oncogenesis in tan-
dem with a second mutation, which is often a large-scale 
deletion or other null allele.
There were no reports of potential SDHD-associated 
cancers in the immediate family although further informa-
tion from extended family members was unavailable. We 
previously reported inherited recessive SDHB mutations in 
association with a paediatric primary mitochondrial pheno-
type and this case also lacked a history of hereditary cancer 
(Alston et al. 2012). It is unclear whether germline carriers 
of the p.(Asp92Gly) SDHD mutation are at elevated risk of 
HNPGL and despite no tumours having been reported in 
the family, it is the opinion of their clinicians that surveil-
lance was advisable and is ongoing.
Left ventricular non-compaction is a rare form of cardio-
myopathy characterised by abnormal trabeculations in the 
left ventricle and associated with either ventricular hyper-
trophy or dilation. In some patients, LVNC arises from a 
failure to complete the final stage of myocardial morpho-
genesis, but this is not a satisfactory explanation for all 
cases, particularly those associated with congenital heart 
defects or arrhythmias. LVNC is genetically heterogene-
ous with many cases remaining genetically undiagnosed, 
but metabolic derangements are common and this form of 
cardiomyopathy is typical of Barth Syndrome, a disorder 
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of mitochondrial cardiolipin typically accompanied by neu-
tropenia (Chen et al. 2002) and has also been observed in 
other mitochondrial disorders including those due to muta-
tions in mtDNA (Pignatelli et al. 2003).
In conclusion, our case further expands the clinical and 
genetic heterogeneity associated with isolated complex II 
deficiency and demonstrates that sequencing analysis of all 
SDH subunits and assembly factors should be undertaken 
for patients in whom an isolated succinate dehydrogenase 
defect has been identified.
Acknowledgments This work was supported by grants (to RWT 
and RM) from The Wellcome Trust Centre for Mitochondrial 
Research (096919Z/11/Z), the Medical Research Council (UK) 
Centre for Translational Muscle Disease Research (G0601943), The 
Lily Foundation and the UK NHS Highly Specialised Commission-
ers which funds the “Rare Mitochondrial Disorders of Adults and 
Children” Diagnostic Service in Newcastle upon Tyne (http://www.
newcastle-mitochondria.com). CLA is the recipient of a National 
Institute for Health Research (NIHR) doctoral fellowship (NIHR-
HCS-D12-03-04). The views expressed are those of the authors and 
not necessarily those of the NHS, the NIHR or the Department of 
Health.
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://crea-
tivecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova 
A, Bork P, Kondrashov AS, Sunyaev SR (2010) A method and 
server for predicting damaging missense mutations. Nat Methods 
7:248–249. doi:10.1038/nmeth0410-248
Alston CL, Davison JE, Meloni F, van der Westhuizen FH, He L, 
Hornig-Do HT, Peet AC, Gissen P, Goffrini P, Ferrero I, Was-
smer E, McFarland R, Taylor RW (2012) Recessive germline 
SDHA and SDHB mutations causing leukodystrophy and iso-
lated mitochondrial complex II deficiency. J Med Genet 49:569–
577. doi:10.1136/jmedgenet-2012-101146
Birch-Machin MA, Taylor RW, Cochran B, Ackrell BA, Turnbull 
DM (2000) Late-onset optic atrophy, ataxia, and myopathy 
associated with a mutation of a complex II gene. Ann Neurol 
48:330–335
Bonneaud N, Ozier-Kalogeropoulos O, Li GY, Labouesse M, 
Minvielle-Sebastia L, Lacroute F (1991) A family of low 
and high copy replicative, integrative and single-stranded S. 
cerevisiae/E. coli shuttle vectors. Yeast 7:609–615. doi:10.1002/
yea.320070609
Bradford MM (1976) A rapid and sensitive method for the quantita-
tion of microgram quantities of protein utilizing the principle of 
protein–dye binding. Anal Biochem 72:248–254
Chen R, Tsuji T, Ichida F, Bowles KR, Yu X, Watanabe S, Hirono K, 
Tsubata S, Hamamichi Y, Ohta J, Imai Y, Bowles NE, Miyawaki 
T, Towbin JA (2002) Mutation analysis of the G4.5 gene in 
patients with isolated left ventricular noncompaction. Mol Genet 
Metab 77:319–325
Ghezzi D, Goffrini P, Uziel G, Horvath R, Klopstock T, Lochmuller 
H, D’Adamo P, Gasparini P, Strom TM, Prokisch H, Invernizzi F, 
Ferrero I, Zeviani M (2009) SDHAF1, encoding a LYR complex-
II specific assembly factor, is mutated in SDH-defective infan-
tile leukoencephalopathy. Nat Genet 41:654–656. doi:10.1038/
ng.378
Gietz RD, Schiestl RH (2007) Quick and easy yeast transformation 
using the LiAc/SS carrier DNA/PEG method. Nat Protoc 2:35–
37. doi:10.1038/nprot.2007.14
Goffrini P, Ercolino T, Panizza E, Giache V, Cavone L, Chiarugi A, 
Dima V, Ferrero I, Mannelli M (2009) Functional study in a 
yeast model of a novel succinate dehydrogenase subunit B gene 
germline missense mutation (C191Y) diagnosed in a patient 
affected by a glomus tumor. Hum Mol Genet 18:1860–1868. 
doi:10.1093/hmg/ddp102
Gorman GS, Schaefer AM, Ng Y, Gomez N, Blakely EL, Alston CL, 
Feeney C, Horvath R, Yu-Wai-Man P, Chinnery PF, Taylor RW, 
Turnbull DM, McFarland R (2015) Prevalence of nuclear and 
mitochondrial DNA mutations related to adult mitochondrial dis-
ease. Ann Neurol 77:753–759. doi:10.1002/ana.24362
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next gen-
eration. Cell 144:646–674. doi:10.1016/j.cell.2011.02.013
Hensen EF, Siemers MD, Jansen JC, Corssmit EP, Romijn JA, Tops 
CM, van der Mey AG, Devilee P, Cornelisse CJ, Bayley JP, 
Vriends AH (2011) Mutations in SDHD are the major deter-
minants of the clinical characteristics of Dutch head and neck 
paraganglioma patients. Clin Endocrinol Oxf 75:650–655. 
doi:10.1111/j.1365-2265.2011.04097.x
Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR (1989) Site-
directed mutagenesis by overlap extension using the polymerase 
chain reaction. Gene 77:51–59
Horscroft JA, Murray AJ (2014) Skeletal muscle energy metabolism 
in environmental hypoxia: climbing towards consensus. Extrem 
Physiol Med 3:19. doi:10.1186/2046-7648-3-19
Jackson CB, Nuoffer JM, Hahn D, Prokisch H, Haberberger B, 
Gautschi M, Haberli A, Gallati S, Schaller A (2014) Mutations in 
SDHD lead to autosomal recessive encephalomyopathy and iso-
lated mitochondrial complex II deficiency. J Med Genet 51:170–
175. doi:10.1136/jmedgenet-2013-101932
Jarreta D, Orus J, Barrientos A, Miro O, Roig E, Heras M, Moraes 
CT, Cardellach F, Casademont J (2000) Mitochondrial function 
in heart muscle from patients with idiopathic dilated cardiomyo-
pathy. Cardiovasc Res 45:860–865
Jones DT (1999) Protein secondary structure prediction based on 
position-specific scoring matrices. J Mol Biol 292:195–202. 
doi:10.1006/jmbi.1999.3091
Kaiser C, Michaelis S, Mitchel A (1994) Methods in yeast genetics: 
a laboratory course manual, 1994, ed edn. Cold Spring Harbor 
Laboratory Press, Cold Spring Harbor
Kirby DM, Thorburn DR, Turnbull DM, Taylor RW (2007) Biochemi-
cal assays of respiratory chain complex activity. Methods Cell 
Biol 80:93–119. doi:10.1016/s0091-679x(06)80004-x
Ma YY, Wu TF, Liu YP, Wang Q, Li XY, Ding Y, Song JQ, Shi XY, 
Zhang WN, Zhao M, Hu LY, Ju J, Wang ZL, Yang YL, Zou LP 
(2014) Two compound frame-shift mutations in succinate dehy-
drogenase gene of a Chinese boy with encephalopathy. Brain 
Dev 36:394–398. doi:10.1016/j.braindev.2013.06.003
Manning NJ, Olpin SE, Pollitt RJ, Webley J (1990) A comparison of 
[9, 10-3H] palmitic and [9, 10-3H] myristic acids for the detec-
tion of defects of fatty acid oxidation in intact cultured fibro-
blasts. J Inherit Metab Dis 13:58–68
Miettinen M, Lasota J (2014) Succinate dehydrogenase deficient gas-
trointestinal stromal tumors (GISTs)—a review. Int J Biochem 
Cell Biol 53:514–519. doi:10.1016/j.biocel.2014.05.033
Ng PC, Henikoff S (2003) SIFT: predicting amino acid changes that 
affect protein function. Nucleic Acids Res 31:3812–3814
879Hum Genet (2015) 134:869–879 
1 3
Nijtmans LG, Henderson NS, Holt IJ (2002) Blue native electropho-
resis to study mitochondrial and other protein complexes. Meth-
ods 26:327–334. doi:10.1016/s1046-2023(02)00038-5
Ohlenbusch A, Edvardson S, Skorpen J, Bjornstad A, Saada A, 
Elpeleg O, Gartner J, Brockmann K (2012) Leukoencepha-
lopathy with accumulated succinate is indicative of SDHAF1 
related complex II deficiency. Orphanet J Rare Dis 7:69. 
doi:10.1186/1750-1172-7-69
Olpin SE, Manning NJ, Carpenter K, Middleton B, Pollitt RJ (1992) 
Differential diagnosis of hydroxydicarboxylic aciduria based on 
release of 3H2O from [9, 10-3H] myristic and [9, 10-3H] pal-
mitic acids by intact cultured fibroblasts. J Inherit Metab Dis 
15:883–890
Olpin SE, Manning NJ, Pollitt RJ, Clarke S (1997) Improved detec-
tion of long-chain fatty acid oxidation defects in intact cells 
using [9, 10-3H] oleic acid. J Inherit Metab Dis 20:415–419
Oyedotun KS, Lemire BD (2001) The quinone-binding sites of the 
Saccharomyces cerevisiae succinate–ubiquinone oxidoreductase. 
J Biol Chem 276:16936–16943. doi:10.1074/jbc.M100184200
Padmanabhan S, Baldwin RL (1994) Helix-stabilizing interaction 
between tyrosine and leucine or valine when the spacing is i, 
i + 4. J Mol Biol 241:706–713. doi:10.1006/jmbi.1994.1545
Pagliarini DJ, Calvo SE, Chang B, Sheth SA, Vafai SB, Ong SE, Wal-
ford GA, Sugiana C, Boneh A, Chen WK, Hill DE, Vidal M, 
Evans JG, Thorburn DR, Carr SA, Mootha VK (2008) A mito-
chondrial protein compendium elucidates complex I disease 
biology. Cell 134:112–123. doi:10.1016/j.cell.2008.06.016
Panizza E, Ercolino T, Mori L, Rapizzi E, Castellano M, Opocher G, 
Ferrero I, Neumann HP, Mannelli M, Goffrini P (2013) Yeast 
model for evaluating the pathogenic significance of SDHB, 
SDHC and SDHD mutations in PHEO–PGL syndrome. Hum 
Mol Genet 22:804–815. doi:10.1093/hmg/dds487
Parfait B, Chretien D, Rotig A, Marsac C, Munnich A, Rustin P 
(2000) Compound heterozygous mutations in the flavoprotein 
gene of the respiratory chain complex II in a patient with Leigh 
syndrome. Hum Genet 106:236–243
Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, 
Meng EC, Ferrin TE (2004) UCSF Chimera—a visualization 
system for exploratory research and analysis. J Comput Chem 
25:1605–1612. doi:10.1002/jcc.20084
Pignatelli RH, McMahon CJ, Dreyer WJ, Denfield SW, Price J, Bel-
mont JW, Craigen WJ, Wu J, El Said H, Bezold LI, Clunie S, 
Fernbach S, Bowles NE, Towbin JA (2003) Clinical characteri-
zation of left ventricular noncompaction in children: a relatively 
common form of cardiomyopathy. Circulation 108:2672–2678. 
doi:10.1161/01.cir.0000100664.10777.b8
Pollard PJ, Briere JJ, Alam NA, Barwell J, Barclay E, Wortham NC, 
Hunt T, Mitchell M, Olpin S, Moat SJ, Hargreaves IP, Heales SJ, 
Chung YL, Griffiths JR, Dalgleish A, McGrath JA, Gleeson MJ, 
Hodgson SV, Poulsom R, Rustin P, Tomlinson IP (2005) Accu-
mulation of Krebs cycle intermediates and over-expression of 
HIF1alpha in tumours which result from germline FH and SDH 
mutations. Hum Mol Genet 14:2231–2239. doi:10.1093/hmg/
ddi227
Renkema GH, Wortmann SB, Smeets RJ, Venselaar H, Antoine 
M, Visser G, Ben-Omran T, van den Heuvel LP, Timmers HJ, 
Smeitink JA, Rodenburg RJ (2014) SDHA mutations causing a 
multisystem mitochondrial disease: novel mutations and genetic 
overlap with hereditary tumors. Eur J Hum Genet. doi:10.1038/
ejhg.2014.80
Skladal D, Halliday J, Thorburn DR (2003) Minimum birth preva-
lence of mitochondrial respiratory chain disorders in children. 
Brain 126:1905–1912. doi:10.1093/brain/awg170
Tavtigian SV, Deffenbaugh AM, Yin L, Judkins T, Scholl T, Samollow 
PB, de Silva D, Zharkikh A, Thomas A (2006) Comprehensive 
statistical study of 452 BRCA1 missense substitutions with clas-
sification of eight recurrent substitutions as neutral. J Med Genet 
43:295–305. doi:10.1136/jmg.2005.033878
Taylor RW, Birch-Machin MA, Schaefer J, Taylor L, Shakir R, Ack-
rell BA, Cochran B, Bindoff LA, Jackson MJ, Griffiths P, Turn-
bull DM (1996) Deficiency of complex II of the mitochondrial 
respiratory chain in late-onset optic atrophy and ataxia. Ann 
Neurol 39:224–232. doi:10.1002/ana.410390212
Xiao M, Yang H, Xu W, Ma S, Lin H, Zhu H, Liu L, Liu Y, Yang C, 
Xu Y, Zhao S, Ye D, Xiong Y, Guan KL (2012) Inhibition of 
alpha-KG-dependent histone and DNA demethylases by fuma-
rate and succinate that are accumulated in mutations of FH and 
SDH tumor suppressors. Genes Dev 26:1326–1338. doi:10.1101/
gad.191056.112
Yang J, Yan R, Roy A, Xu D, Poisson J, Zhang Y (2014) The 
I-TASSER suite: protein structure and function prediction. Nat 
Methods 12:7–8. doi:10.1038/nmeth.3213
